Clinical Implications of Minimal Residual Disease Detection in Infants With


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
20 02 2021
Historique:
pubmed: 7 1 2021
medline: 16 9 2021
entrez: 6 1 2021
Statut: ppublish

Résumé

Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of MRD was measured in 249 infants by DNA-based polymerase chain reaction of rearranged EOI MRD levels predicted outcome with 6-year disease-free survival (DFS) of 60.2% (95% CI, 43.2 to 73.6), 45.0% (95% CI, 28.3 to 53.1), and 33.8% (95% CI, 23.8 to 44.1) for infants with negative, intermediate, and high EOI MRD levels, respectively ( This study provides support for the idea that induction therapy selects patients for subsequent therapy; infants with high EOI MRD may benefit from AML-like consolidation (DFS 45.9%

Identifiants

pubmed: 33405950
doi: 10.1200/JCO.20.02333
pmc: PMC8196086
doi:

Banques de données

EudraCT
['2005-004599-19']
ClinicalTrials.gov
['NCT00550992']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

652-662

Commentaires et corrections

Type : ErratumIn

Références

Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Leukemia. 2006 Mar;20(3):451-7
pubmed: 16424875
J Clin Oncol. 2020 Feb 20;38(6):602-612
pubmed: 31825704
Blood. 2010 Apr 22;115(16):3206-14
pubmed: 20154213
Int J Oncol. 2000 Dec;17(6):1277-87
pubmed: 11078816
Blood. 2011 Aug 25;118(8):2077-84
pubmed: 21719599
J Clin Oncol. 2016 Aug 1;34(22):2591-601
pubmed: 27269950
Br J Haematol. 2005 Oct;131(2):185-92
pubmed: 16197448
Bone Marrow Transplant. 2017 Jul;52(7):962-968
pubmed: 28244980
Haematologica. 2019 May;104(5):986-992
pubmed: 30545921
Lancet. 2007 Jul 21;370(9583):240-250
pubmed: 17658395
Leukemia. 2007 Apr;21(4):604-11
pubmed: 17287850
Leukemia. 2008 Mar;22(3):641-4
pubmed: 17851557
Haematologica. 2018 Jan;103(1):107-115
pubmed: 29079599
J Clin Oncol. 2018 Jan 20;36(3):244-253
pubmed: 29148893
Leukemia. 2009 Jun;23(6):1073-9
pubmed: 19212338
Cytometry B Clin Cytom. 2018 Jan;94(1):82-93
pubmed: 28187514
J Clin Oncol. 2019 Sep 1;37(25):2246-2256
pubmed: 31283407
Leukemia. 2020 Nov;34(11):3042-3046
pubmed: 32533093
Blood. 2020 Apr 23;135(17):1438-1446
pubmed: 32315382
Methods Mol Biol. 2009;538:115-50
pubmed: 19277574
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54
pubmed: 15626757
Lancet. 1998 Nov 28;352(9142):1731-8
pubmed: 9848348

Auteurs

Janine Stutterheim (J)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Inge M van der Sluis (IM)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Paola de Lorenzo (P)

Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy.
Pediatrics, School of Medicine and Surgery, University of Milano-Bicocca, Fondazione MBBM/San Gerardo Hospital, Monza, Italy.

Julia Alten (J)

Department of Pediatrics, UKSH, Kiel, Germany.

Philip Ancliffe (P)

United Kingdom Children Cancer Study Group, London, United Kingdom.

Andishe Attarbaschi (A)

St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Benoit Brethon (B)

Department of Pediatric Hematology, University Robert Debre Hospital, APHP, Paris, France.

Andrea Biondi (A)

Pediatrics, School of Medicine and Surgery, University of Milano-Bicocca, Fondazione MBBM/San Gerardo Hospital, Monza, Italy.

Myriam Campbell (M)

Chilean National Pediatric Oncology Group, Santiago, Chile.

Giovanni Cazzaniga (G)

Tettamanti Research Center, Pediatrics, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Gabriele Escherich (G)

German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg, Germany.

Alina Ferster (A)

European Organisation for Research and Treatment of Cancer Children Leukemia Group, Brussels, Belgium.

Rishi S Kotecha (RS)

Australian and New Zealand Children's Haematology/Oncology Group, Perth Children's Hospital, Perth, Australia.
Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia.

Birgitte Lausen (B)

Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Chi Kong Li (CK)

The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China.

Luca Lo Nigro (L)

Cytogenetic-Cytouorimetric-Molecular Biology Laboratory, Center of Pediatric Hematology Oncology, Azienda Policlinico "G. Rodolico - San Marco," Catania, Italy.

Franco Locatelli (F)

Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Sapienza, University of Rome, Rome, Italy.

Rolf Marschalek (R)

DCAL, Institute of Pharmaceutical Biology, Goethe-University, Frankfurt am Main, Germany.

Claus Meyer (C)

DCAL, Institute of Pharmaceutical Biology, Goethe-University, Frankfurt am Main, Germany.

Martin Schrappe (M)

Berlin-Frankfurt-Miünster Group Germany, Kiel, Germany.

Jan Stary (J)

Czech Working Group for Pediatric Hematology, Prague, Czech Republic.

Ajay Vora (A)

United Kingdom Children Cancer Study Group, London, United Kingdom.

Jan Zuna (J)

CLIP, Dept. of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Vincent H J van der Velden (VHJ)

Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Tomasz Szczepanski (T)

Polish Pediatric Leukemia/Lymphoma Study Group, Zabrze, Medical University of Silesia, Katowice, Poland.

Maria Grazia Valsecchi (MG)

Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy.

Rob Pieters (R)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Dutch Childhood Oncology Group, Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH